EFFECTS OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ON LIPOPROTEIN PARTICLE CONCENTRATIONS DETERMINED BY NUCLEAR MAGNETIC RESONANCE: SUBSTUDY OF A RANDOMIZED DOUBLE-BLIND PHASE II CLINICAL TRIAL

Michael J. Koren, Dean Kereiakes, Ray Pourfarzib, Deborah Winegar, Poulabi Banerjee, Sara Hamon, Corinne Hanotin, James M. McKenney
  • Journal of the American College of Cardiology, April 2014, Elsevier
  • DOI: 10.1016/s0735-1097(14)61373-5

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/s0735-1097(14)61373-5

The following have contributed to this page: Dr Ray Pourfarzib